We have made game-changing discoveries that revolutionised the way cancer is studied and treated. We were the first to provide evidence that DNA damage causes cancer, and the first in Europe to develop chemotherapeutic agents, some of which are still in use more than 50 years later.
We discover more new cancer drugs than any other academic centre in the world. Since 2005 we have discovered 20 cancer drug candidates, progressed nine drugs into clinical trials, and had abiraterone, a pioneering prostate cancer drug, approved by NICE for use in the NHS.
Queen's Anniversary Prize
In November 2017 we were recognised with the highly prestigious Queen's Anniversary Prize for our pre-eminent work in cancer drug discovery with benefits to patients globally.
The prize is presented to universities and colleges judged to be outstanding with respect to excellence, innovation and tangible beneficial effects in the wider world
Awarded every two years, the prize will be presented to the ICR in February 2018 at a ceremony to be held at Buckingham Palace.
The ICR is also the leading academic research centre in the UK. We ranked first in the Times Higher Education league table for performance in the last Research Excellence Framework. And we are the leading academic institution in the UK, in terms of the impact of our papers in biological sciences and clinical medicine on our peers. Together with The Royal Marsden, we rank in the top four centres in the world for cancer research and treatment.
The ICR is focused on taking our research results to patients as quickly as possible. We work with pharmaceutical companies to develop new treatments for patients, and are the most successful university in the UK at generating invention income from our discoveries – income which we plough back into our research.